Immunitybio

Immunitybio Employees

The The number of employees of Immunitybio (IBRX) as of Oct 18, 2026 is 691. In the previous year, The number of employees was 691.00 — a change of 0.00% (lower).

Employees

691

YoY

0.00%

Last updated:

In 2025, Immunitybio employed 691 people, a 0.00% change from the 691.00 number of employees in the previous year.

The Immunitybio Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2018
691.00 USD
Jan 1, 2019
691.00 USD
Jan 1, 2020
691.00 USD
Jan 1, 2021
691.00 USD
Jan 1, 2022
691.00 USD
Jan 1, 2023
691.00 USD
Jan 1, 2024
691.00 USD
Jan 1, 2025
691.00 USD
The Immunitybio Employees history
YEAREmployeesYoY
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
6910.00%
691—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Employees Details

Examining Immunitybio's Employee Base

Immunitybio's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Immunitybio's operational capacity and future potential.

Year-to-Year Comparison

Assessing Immunitybio's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Immunitybio's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Immunitybio’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Immunitybio stock

The number of employees of Immunitybio is 691 in 2025.

The number of employees of Immunitybio changed from 691.00 to 691, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees Immunitybio since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's Immunitybio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Immunitybio

All Key Metrics — Immunitybio